Masimo Corporation (MASI)
USD 153.68
(1.45%)
USD 153.68
(1.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.67 Billion USD | -10.42% |
| 2022 | 1.87 Billion USD | 455.79% |
| 2021 | 336.76 Million USD | 10.45% |
| 2020 | 304.91 Million USD | 33.58% |
| 2019 | 228.25 Million USD | 22.88% |
| 2018 | 185.75 Million USD | -8.64% |
| 2017 | 203.32 Million USD | -21.89% |
| 2016 | 260.28 Million USD | -20.16% |
| 2015 | 326.02 Million USD | 26.73% |
| 2014 | 257.26 Million USD | 129.17% |
| 2013 | 112.26 Million USD | 11.95% |
| 2012 | 100.27 Million USD | 16.01% |
| 2011 | 86.43 Million USD | 7.78% |
| 2010 | 80.19 Million USD | 20.31% |
| 2009 | 66.65 Million USD | -9.87% |
| 2008 | 73.95 Million USD | -13.44% |
| 2007 | 85.44 Million USD | -16.32% |
| 2006 | 102.11 Million USD | -49.37% |
| 2005 | 201.67 Million USD | 0.0% |
| 2003 | 155.79 Million USD | 17.32% |
| 2002 | 132.79 Million USD | 0.0% |
| 1999 | 5.1 Million USD | 59.38% |
| 1998 | 3.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.52 Billion USD | -4.23% |
| 2024 Q1 | 1.59 Billion USD | -5.02% |
| 2024 Q3 | 1.62 Billion USD | 6.52% |
| 2023 Q4 | 1.67 Billion USD | -2.53% |
| 2023 Q2 | 1.7 Billion USD | -4.61% |
| 2023 Q3 | 1.72 Billion USD | 1.02% |
| 2023 Q1 | 1.78 Billion USD | -4.62% |
| 2023 FY | 1.67 Billion USD | -10.42% |
| 2022 Q1 | 326.65 Million USD | -3.0% |
| 2022 Q2 | 1.75 Billion USD | 438.3% |
| 2022 Q3 | 1.8 Billion USD | 2.58% |
| 2022 Q4 | 1.87 Billion USD | 3.76% |
| 2022 FY | 1.87 Billion USD | 455.79% |
| 2021 Q1 | 269.68 Million USD | -11.55% |
| 2021 Q4 | 336.76 Million USD | 12.77% |
| 2021 Q3 | 298.63 Million USD | 2.82% |
| 2021 FY | 336.76 Million USD | 10.45% |
| 2021 Q2 | 290.45 Million USD | 7.7% |
| 2020 Q2 | 291.08 Million USD | 31.56% |
| 2020 Q1 | 221.26 Million USD | -3.06% |
| 2020 FY | 304.91 Million USD | 33.58% |
| 2020 Q4 | 304.91 Million USD | 2.2% |
| 2020 Q3 | 298.33 Million USD | 2.49% |
| 2019 FY | 228.25 Million USD | 22.88% |
| 2019 Q1 | 174.3 Million USD | -6.17% |
| 2019 Q4 | 228.25 Million USD | 10.88% |
| 2019 Q3 | 205.85 Million USD | 8.36% |
| 2019 Q2 | 189.97 Million USD | 8.99% |
| 2018 Q4 | 185.75 Million USD | 1.25% |
| 2018 Q3 | 183.46 Million USD | 0.73% |
| 2018 FY | 185.75 Million USD | -8.64% |
| 2018 Q1 | 183.04 Million USD | -9.97% |
| 2018 Q2 | 182.12 Million USD | -0.5% |
| 2017 Q1 | 243.71 Million USD | -6.37% |
| 2017 Q4 | 203.32 Million USD | 7.7% |
| 2017 Q3 | 188.78 Million USD | 1.36% |
| 2017 FY | 203.32 Million USD | -21.89% |
| 2017 Q2 | 186.26 Million USD | -23.57% |
| 2016 Q2 | 307.53 Million USD | -12.95% |
| 2016 FY | 260.28 Million USD | -20.16% |
| 2016 Q4 | 260.28 Million USD | -15.01% |
| 2016 Q3 | 306.26 Million USD | -0.41% |
| 2016 Q1 | 353.27 Million USD | 8.36% |
| 2015 Q4 | 326.02 Million USD | 5.32% |
| 2015 FY | 326.02 Million USD | 26.73% |
| 2015 Q1 | 250.52 Million USD | -2.62% |
| 2015 Q2 | 299.55 Million USD | 19.57% |
| 2015 Q3 | 309.55 Million USD | 3.34% |
| 2014 Q2 | 179.36 Million USD | 70.49% |
| 2014 Q1 | 105.21 Million USD | -6.28% |
| 2014 FY | 257.26 Million USD | 129.17% |
| 2014 Q4 | 257.26 Million USD | 3.58% |
| 2014 Q3 | 248.36 Million USD | 38.47% |
| 2013 Q1 | 107.26 Million USD | 6.96% |
| 2013 FY | 112.26 Million USD | 11.95% |
| 2013 Q4 | 112.26 Million USD | -1.41% |
| 2013 Q3 | 113.87 Million USD | 9.76% |
| 2013 Q2 | 103.74 Million USD | -3.28% |
| 2012 Q1 | 102.61 Million USD | 18.71% |
| 2012 Q4 | 100.27 Million USD | 5.17% |
| 2012 Q3 | 95.34 Million USD | 11.06% |
| 2012 Q2 | 85.84 Million USD | -16.34% |
| 2012 FY | 100.27 Million USD | 16.01% |
| 2011 FY | 86.43 Million USD | 7.78% |
| 2011 Q1 | 73.31 Million USD | -8.58% |
| 2011 Q2 | 72.64 Million USD | -0.91% |
| 2011 Q3 | 76.73 Million USD | 5.63% |
| 2011 Q4 | 86.43 Million USD | 12.65% |
| 2010 Q4 | 80.19 Million USD | 0.89% |
| 2010 FY | 80.19 Million USD | 20.31% |
| 2010 Q3 | 79.48 Million USD | 7.71% |
| 2010 Q1 | 82.75 Million USD | 24.15% |
| 2010 Q2 | 73.79 Million USD | -10.83% |
| 2009 FY | 66.65 Million USD | -9.87% |
| 2009 Q1 | 68.8 Million USD | -6.97% |
| 2009 Q4 | 66.65 Million USD | 2.06% |
| 2009 Q3 | 65.3 Million USD | 5.35% |
| 2009 Q2 | 61.99 Million USD | -9.9% |
| 2008 FY | 73.95 Million USD | -13.44% |
| 2008 Q2 | 62.23 Million USD | 4.7% |
| 2008 Q1 | 59.44 Million USD | -30.43% |
| 2008 Q4 | 73.95 Million USD | 28.79% |
| 2008 Q3 | 57.42 Million USD | -7.74% |
| 2007 Q3 | 88.03 Million USD | -9.08% |
| 2007 Q1 | 85.99 Million USD | -15.78% |
| 2007 Q2 | 96.82 Million USD | 12.6% |
| 2007 Q4 | 85.44 Million USD | -2.95% |
| 2007 FY | 85.44 Million USD | -16.32% |
| 2006 Q4 | 102.11 Million USD | 0.0% |
| 2006 FY | 102.11 Million USD | -49.37% |
| 2005 Q4 | 201.67 Million USD | 0.0% |
| 2005 FY | 201.67 Million USD | 0.0% |
| 2003 FY | 155.79 Million USD | 17.32% |
| 2002 FY | 132.79 Million USD | 0.0% |
| 1999 FY | 5.1 Million USD | 59.38% |
| 1998 FY | 3.2 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | -1224.418% |
| AngioDynamics, Inc. | 112.08 Million USD | -1395.918% |
| AtriCure, Inc. | 147.76 Million USD | -1034.715% |
| Avinger, Inc. | 19.97 Million USD | -8295.253% |
| Azenta, Inc. | 351.22 Million USD | -377.393% |
| BioLife Solutions, Inc. | 75.05 Million USD | -2134.081% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 59.184% |
| Daxor Corporation | 858.75 Thousand USD | -195147.089% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | -10178.936% |
| Femasys Inc. | 9.4 Million USD | -17731.096% |
| GlucoTrack, Inc. | 1.7 Million USD | -98067.447% |
| Harvard Bioscience, Inc. | 64.29 Million USD | -2507.945% |
| Hologic, Inc. | 4.02 Billion USD | 58.353% |
| ICU Medical, Inc. | 2.25 Billion USD | 25.646% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 17.978% |
| KORU Medical Systems, Inc. | 8.1 Million USD | -20581.614% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | -3330.378% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -253970.092% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -253970.092% |
| Microbot Medical Inc. | 3.82 Million USD | -43723.837% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | -6586.087% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | -49.273% |
| Nephros, Inc. | 3.5 Million USD | -47764.687% |
| NovoCure Limited | 783.63 Million USD | -113.965% |
| NEXGEL, Inc. | 4.78 Million USD | -34911.485% |
| NEXGEL, Inc. | 4.78 Million USD | -34911.485% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | -1839.256% |
| OraSure Technologies, Inc. | 52.17 Million USD | -3113.67% |
| Pro-Dex, Inc. | 23.34 Million USD | -7082.881% |
| Pulse Biosciences, Inc. | 16.44 Million USD | -10096.425% |
| Predictive Oncology Inc. | 6.14 Million USD | -27183.516% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | -24396.018% |
| QuidelOrtho Corporation | 3.55 Billion USD | 52.865% |
| Repligen Corporation | 853.2 Million USD | -96.517% |
| Sanara MedTech Inc. | 29.28 Million USD | -5625.822% |
| STAAR Surgical Company | 102.73 Million USD | -1532.015% |
| Sharps Technology, Inc. | 3.85 Million USD | -43394.367% |
| Utah Medical Products, Inc. | 7.14 Million USD | -23366.76% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 58.864% |
| Jin Medical International Ltd. | 8.92 Million USD | -18687.933% |